The study with BelCHOP* (belinostat plus Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone) is designed to determine what dose of belinostat combined with CHOP can be safely administered together for first-line treatment of patients with PTCL. The purpose is furthermore to establish the recommended dose for a phase III confirmatory study in the indication. The BelCHOP study is a precondition for a phase III confirmatory study with belinostat in PTCL. The BelCHOP study is expected to recruit up to 28 patients.
Help employers find you! Check out all the jobs and post your resume.
